These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32767679)

  • 1. A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.
    Berstein G; Zhang Y; Berger Z; Kieras E; Li G; Samuel A; Yeoh T; Dowty H; Beaumont K; Wigger-Alberti W; von Mackensen Y; Kroencke U; Hamscho R; Garcet S; Krueger JG; Banfield C; Oemar B
    Clin Exp Dermatol; 2021 Jan; 46(1):122-129. PubMed ID: 32767679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin.
    Smith SH; Peredo CE; Takeda Y; Bui T; Neil J; Rickard D; Millerman E; Therrien JP; Nicodeme E; Brusq JM; Birault V; Viviani F; Hofland H; Jetten AM; Cote-Sierra J
    PLoS One; 2016; 11(2):e0147979. PubMed ID: 26870941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.
    Ma L; Xue H; Qi R; Wang Y; Yuan L
    J Transl Med; 2018 Mar; 16(1):59. PubMed ID: 29523162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.
    Skepner J; Ramesh R; Trocha M; Schmidt D; Baloglu E; Lobera M; Carlson T; Hill J; Orband-Miller LA; Barnes A; Boudjelal M; Sundrud M; Ghosh S; Yang J
    J Immunol; 2014 Mar; 192(6):2564-75. PubMed ID: 24516202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis.
    Liu S; Liu D; Shen R; Li D; Hu Q; Yan Y; Sun J; Zhang F; Wan H; Dong P; Feng J; Zhang R; Li J; Zhang L; Tao W
    Sci Rep; 2021 Apr; 11(1):9132. PubMed ID: 33911101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF; Gebauer K; Spelman L; Zane LT
    J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel RORγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations.
    Imura C; Ueyama A; Sasaki Y; Shimizu M; Furue Y; Tai N; Tsujii K; Katayama K; Okuno T; Shichijo M; Yasui K; Yamamoto M
    J Dermatol Sci; 2019 Mar; 93(3):176-185. PubMed ID: 30905492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
    Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
    J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
    Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
    J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice.
    Pantelyushin S; Haak S; Ingold B; Kulig P; Heppner FL; Navarini AA; Becher B
    J Clin Invest; 2012 Jun; 122(6):2252-6. PubMed ID: 22546855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
    Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
    Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis.
    Tang L; Yang X; Liang Y; Xie H; Dai Z; Zheng G
    Front Immunol; 2018; 9():1210. PubMed ID: 29899748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses.
    Ecoeur F; Weiss J; Kaupmann K; Hintermann S; Orain D; Guntermann C
    Front Immunol; 2019; 10():577. PubMed ID: 30972071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis.
    Xue X; Soroosh P; De Leon-Tabaldo A; Luna-Roman R; Sablad M; Rozenkrants N; Yu J; Castro G; Banie H; Fung-Leung WP; Santamaria-Babi L; Schlueter T; Albers M; Leonard K; Budelsky AL; Fourie AM
    Sci Rep; 2016 Dec; 6():37977. PubMed ID: 27905482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers.
    Zane LT; Hughes MH; Shakib S
    Am J Clin Dermatol; 2016 Oct; 17(5):519-526. PubMed ID: 27335049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
    Xue X; De Leon-Tabaldo A; Luna-Roman R; Castro G; Albers M; Schoetens F; DePrimo S; Devineni D; Wilde T; Goldberg S; Kinzel O; Hoffmann T; Fourie AM; Thurmond RL
    Sci Rep; 2021 May; 11(1):11066. PubMed ID: 34040108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
    Snape SD; Wigger-Alberti W; Goehring UM
    Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group.
    Molin L; Cutler TP; Helander I; Nyfors B; Downes N
    Br J Dermatol; 1997 Jan; 136(1):89-93. PubMed ID: 9039301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
    Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
    Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.